









Markets
/
Stocks
/
nasdaq-rmd
/

Resmed Inc

RMD

View Detailed Chart

279.200USD

+7.260+2.67%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

40.94BMarket Cap

31.17P/E TTM



Resmed Inc

279.200

+7.260+2.67%

Overview Company Financials

Financials

Intraday

30m

Today

+2.67%

5 Days

+1.47%

1 Month

+8.95%

6 Months

+18.21%

Year to Date

+22.09%

1 Year

+30.13%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 19 analysts

BUY

Current Rating

283.512

Target Price

4.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Resmed Inc

RMD

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(1)

Buy(9)

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

2.400

Buy

RSI(14)

71.083

Buy

STOCH(KDJ)(9,3,3)

83.849

Overbought

ATR(14)

5.588

Low Volatility

CCI(14)

83.628

Neutral

Williams %R

8.512

Overbought

TRIX(12,20)

0.353

Sell

StochRSI(14)

50.687

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

275.956

Buy

MA10

273.028

Buy

MA20

264.322

Buy

MA50

256.281

Buy

MA100

241.753

Buy

MA200

240.642

Buy

News

[IN-DEPTH ANALYSIS] ResMed: The Leader in Sleep Health, Powering Future Investment Growth

The current P/E ratio is 21x, lower than the five-year average of 32x. The target price for fiscal year 2026 is expected to be $295 (with a P/E ratio of 27x).

TradingKeyWed, Jun 4

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

Ticker SymbolRMD

CompanyResmed Inc

CEOMr. Michael J. (Mick) Farrell

Websitehttps://www.resmed.com/